Suppr超能文献

一种用于循环黑色素瘤细胞微流控富集和基因分析的模型工作流程。

A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells.

作者信息

Poggiana Cristina, Piazza Alessandro Francesco, Catoni Cristina, Gallingani Ilaria, Piccin Luisa, Pellegrini Stefania, Aneloni Vittorio, Salizzato Valentina, Pigozzo Jacopo, Fabozzi Alessio, Facchinetti Antonella, Menin Chiara, Del Fiore Paolo, Mocellin Simone, Chiarion-Sileni Vanna, Rosato Antonio, Scaini Maria Chiara

机构信息

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.

Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.

出版信息

Sci Rep. 2025 May 2;15(1):15329. doi: 10.1038/s41598-025-99153-y.

Abstract

Circulating melanoma cells (CMCs) are responsible for the hematogenous spread of melanoma and, ultimately, metastasis. However, their study has been limited by the low abundance in patient blood and the heterogeneous expression of surface markers. The FDA-approved CellSearch platform enriches CD146-positive CMCs, whose number correlates with progression-free survival and overall survival. However, a single marker may not be sufficient to identify them all. The Parsortix system allows enrichment of CMCs based on their size and deformability, keeping them viable and suitable for downstream molecular analyses. In this study, we tested the strengths, weaknesses and potential convergences of both platforms to integrate the counting of CMCs with a protocol for their genetic analysis. Samples run on Parsortix were labeled with a customized melanoma antibody cocktail, which efficiently labeled and distinguished CMCs from endothelial cells/leukocytes. The capture rate of CellSearch and Parsortix was comparable for cell lines, but Parsortix had a higher capture rate in real-life samples. Moreover, double enrichment with both CellSearch and Parsortix succeeded in removing most of the leukocyte contamination, resulting in an almost pure CMC sample suitable for genetic analysis. In this regard, a proof-of-concept analysis of CMCs from a paradigmatic case of a metastatic uveal melanoma patient led to the identification of multiple genetic alterations. In particular, the GNAQ p.Q209L was identified as homozygous, while a deletion in BAP1 exon 9 was found hemizygous. Moreover, an isochromosome 8 and a homozygous deletion of the CDKN2A gene were detected. In conclusion, we have optimized an approach to successfully enrich and retrieve viable CMCs from metastatic melanoma patients. Moreover, this study provides proof-of-principle for the feasibility of a marker-agnostic CMC enrichment followed by CMC phenotypic identification and genetic analysis.Kindly check and confirm the processed contributed equally is correctly identify We confirm.

摘要

循环黑色素瘤细胞(CMCs)是黑色素瘤血行转移及最终发生远处转移的原因。然而,对它们的研究受到患者血液中细胞数量稀少以及表面标志物表达异质性的限制。美国食品药品监督管理局(FDA)批准的CellSearch平台可富集CD146阳性的CMCs,其数量与无进展生存期和总生存期相关。然而,单一标志物可能不足以识别所有的CMCs。Parsortix系统可根据CMCs的大小和可变形性对其进行富集,使其保持活力并适合进行下游分子分析。在本研究中,我们测试了这两种平台的优缺点及潜在的融合点,以便将CMCs计数与基因分析方案相结合。在Parsortix上运行的样本用定制的黑色素瘤抗体混合物进行标记,该混合物能有效标记CMCs并将其与内皮细胞/白细胞区分开来。对于细胞系,CellSearch和Parsortix的捕获率相当,但在实际样本中Parsortix的捕获率更高。此外,使用CellSearch和Parsortix进行双重富集成功去除了大部分白细胞污染,得到了几乎纯净的适合基因分析的CMCs样本。在这方面,对一名转移性葡萄膜黑色素瘤患者典型病例的CMCs进行的概念验证分析,发现了多个基因改变。具体而言,GNAQ基因的p.Q209L被鉴定为纯合突变,而BAP1基因第9外显子的缺失被发现为半合子。此外,还检测到8号等臂染色体和CDKN2A基因的纯合缺失。总之,我们优化了一种方法,可成功从转移性黑色素瘤患者中富集并获取有活力的CMCs。此外,本研究为无标志物的CMCs富集、随后进行CMCs表型鉴定和基因分析的可行性提供了原理证明。请检查并确认“贡献相同”已正确识别 我们确认。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7484/12048555/7947ab1a82a1/41598_2025_99153_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验